J
Julian A. Marin-Acevedo
Researcher at Mayo Clinic
Publications - 23
Citations - 1205
Julian A. Marin-Acevedo is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Lung cancer & Immunotherapy. The author has an hindex of 7, co-authored 19 publications receiving 657 citations. Previous affiliations of Julian A. Marin-Acevedo include University of South Florida.
Papers
More filters
Journal ArticleDOI
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo,Bhagirathbhai Dholaria,Aixa E. Soyano,Keith L. Knutson,Saranya Chumsri,Yanyan Lou +5 more
TL;DR: A comprehensive review of immune checkpoint pathways involved in cancer immunotherapy is provided, and their mechanisms and the therapeutic interventions currently under investigation in phase I/II clinical trials are discussed.
Journal ArticleDOI
Next generation of immune checkpoint inhibitors and beyond.
TL;DR: A review of immune checkpoint inhibition therapy can be found in this paper, where the authors aim to elucidate these novel immune inhibitory pathways, potential therapeutic molecules that are under development, and outline particular advantages and challenges with the use of each one of them.
Journal ArticleDOI
Cancer immunotherapy beyond immune checkpoint inhibitors
TL;DR: This review is to include first-in-human phase I and phase I/II clinical trials intended to allow the identification of those drugs that most likely will continue to develop and possibly join the immunotherapeutic arsenal in a near future.
Journal ArticleDOI
Immune Checkpoint Inhibitor Toxicities
TL;DR: A focused review of immune checkpoint inhibitors is provided to familiarize practicing clinicians with this important topic given that the use of immune checkpoints inhibitors continues to increase.
Journal ArticleDOI
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
Aixa E. Soyano,Bhagirathbhai Dholaria,Julian A. Marin-Acevedo,Nancy N. Diehl,David O. Hodge,Yan Luo,Rami Manochakian,Saranya Chumsri,Alex A. Adjei,Keith L. Knutson,Yanyan Lou +10 more
TL;DR: Increased baseline ANC: ALC ratio and M: L ratio before initiation of anti-PD1 antibodies were associated with poor PFS and OS in advanced NSCLC patients, and their potential predictive value might help with risk stratification and treatment strategies.